Investigators analyzed the inactivation of tumor suppressor genes and its transcriptional consequences in thousands of tumors from 33 cancer types or subtypes.
A new analysis suggests that some mutations that seem to occur in tumors might actually stem from infiltrating blood cells affected by myeloproliferative neoplasms.
DNA sequence data from hundreds of individuals suggest that age, smoking, and alcohol use coincide with the expansion of clones containing NOTCH1 and PPM1D mutations.
Researchers tested the combined PGS and PGD assay in a pilot study and now aim to validate it on larger numbers of disorders and compare it to conventional testing.
The firm is developing and beta-testing a line of guide RNA libraries to support CRISPR-based targeted capture and sequencing approaches.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.
The company no longer plans to develop cell-free DNA assays for oncology but will instead look to commercialize a new target capture technology.
A multi-omic analysis implicated a handful of transcription factors, along with genes and regulatory RNAs down- and upstream of them, in metastatic colorectal cancer.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.